Trial Profile
A Phase II Trial of Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jan 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Temsirolimus (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 29 Aug 2016 Status changed from active, no longer recruiting to completed.
- 26 Jan 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Jul 2014 to 1 Jan 2016.
- 26 Jan 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Jan 2014 to 1 Jul 2015.